Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Primary Inclusion Criteria: * Relapsed or refractory histologically confirmed Non-Hodgkin's Lymphoma * Previously treated with at least 1 therapeutic regimen and relapsed or progressed or failed to achieve a response after the last regimen * 18 years of age or older Primary Exclusion Criteria: * Received a non-FDA approved investigational agent within the last 4 weeks * Received cancer therapies (chemotherapy, biological therapy \[including hormonotherapy\], radiation therapy or immunosuppressants within the last 3 weeks, 8 weeks for monoclonal antibodies, radioimmunotherapy or nitrosourea * Eligible for a hematopoietic stem cell transplant (HSCT) or have had an autologous HSCT within the last 16 weeks * Prior history of an allogeneic HSCT * HIV, AIDS-related lymphoma, central nervous system (CNS) lymphoma, Hepatitis-B or Hepatitis-C * Infection requiring antibiotics within the last 4 weeks * Major surgery within the last 4 weeks * Pregnant or breast-feeding women * History of other cancers within the past 5 years